Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11102439 | 1.00 | MAPT (0.48) | MAPTRXFP1NAAASIGMAR1IDO1 | |
| SCHEMBL97331 | 1.00 | MAPT (0.48) | MAPTRXFP1NAAASIGMAR1IDO1 | |
| SCHEMBL11108660 | 1.00 | MAPT (0.48) | MAPTRXFP1NAAASIGMAR1IDO1 | |
| SCHEMBL11103301 | 1.00 | MAPT (0.48) | MAPTRXFP1NAAASIGMAR1IDO1 | |
| SCHEMBL11103088 | 1.00 | MAPT (0.48) | MAPTRXFP1NAAASIGMAR1IDO1 | |
| SCHEMBL2516 | 0.98 | IDO1 (0.48) | MAPTRXFP1NAAASIGMAR1IDO1 | |
| SCHEMBL5544774 | 0.95 | TDP1 (0.49) | MAPTRXFP1NAAASIGMAR1IDO1 | |
| SCHEMBL95268 | 0.95 | TDP1 (0.49) | MAPTRXFP1NAAASIGMAR1IDO1 | |
| SCHEMBL5537350 | 0.95 | TDP1 (0.49) | MAPTRXFP1NAAASIGMAR1IDO1 | |
| SCHEMBL5545715 | 0.95 | TDP1 (0.49) | MAPTRXFP1NAAASIGMAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024075815-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | 国立大学法人大阪大学 | 2024-04-11 | — | — | WO | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| CN-105408325-B | cyanotriazole compounds | 大塚制药株式会社 | 2019-10-22 | — | — | CN | disclosed |
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9603833-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2017-03-28 | — | — | US | disclosed |
| WO-2016194390-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CANCER | R-TECH UENO, LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-9412487-B2 | Silver-(conjugated compound) composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-09 | — | — | US | disclosed |
| EP-0435333-A2 | Cephalosporin derivatives, the process for preparing the same, and antimicrobial composition containing the derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-03 | — | — | EP | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| US-4977179-A | Inhibiting angiotensin converting enzyme | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1990-12-11 | — | — | US | disclosed |
| US-4950662-A | ANTIBIOTIC | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-21 | — | — | US | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4898859-A | 2-Oxa-isocephem compounds and compositions containing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-06 | — | — | US | disclosed |
| US-4859759-A | Siloxane containing benzotriazolyl/tetraalkylpiperidyl substituent | KIMBERLY-CLARK CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0313081-A2 | 2-Oxa-isocephem compounds, compositions containing the same and processes for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-26 | — | — | EP | disclosed |
| EP-0287951-A2 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MAPT 2196/4885RXFP1 2555/4885NAAA 1308/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | MAPT 2196/4885RXFP1 2555/4885NAAA 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.